RxDoctor Payments Data

Miranda Plumley

Nurse Practitioner · Beckley, WVNPI 1407588486

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,029 of the $2,593 with a category attached, or 78.3%. It is spread thinly across 32 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,593in general payments, 2019–2025

Across 101 payments — averaging $25.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$445
  • Johnson & Johnson$345
  • Novartis$252
  • Pfizer$168
  • Merck$165
  • AstraZeneca$128
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,02978%
  • Education$56422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,593 in reported general payments places this provider in the 90th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$38,897
Medicare patients
245
Services billed
1,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$17,652
Anastrozole63$688
Hydroxyurea17$284
Levothyroxine Sodium22$179
Potassium Chloride27$119
Prednisone29$105
Letrozole12$59
Diclofenac Sodium11$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$168$17,65221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →